Login / Signup

Unexpectedly long persistence of anti-SARS-CoV-2 spike monoclonal antibodies tixagevimab and cilgavimab in immunocompromised patients.

Quentin PerrierJulien LupoOlivier Epaulard
Published in: Transplant infectious disease : an official journal of the Transplantation Society (2023)
Keyphrases
  • sars cov
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • chronic kidney disease
  • prognostic factors
  • respiratory syndrome coronavirus
  • respiratory failure